A new treatment for mutant Ras multiple myeloma
A novel monobody-drug conjugate to treat mutant Ras multiple myeloma
['FUNDING_SBIR_2'] · TEZCAT LABORATORIES LLC · NIH-10891604
This study is testing a new treatment for patients with a specific type of multiple myeloma that has a mutant Ras gene, using a special drug that aims to deliver powerful medicine directly to the cancer cells, and it could help those who haven't had success with other treatments.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TEZCAT LABORATORIES LLC (nih funded) |
| Locations | 1 site (NEW HAVEN, UNITED STATES) |
| Trial ID | NIH-10891604 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel biologic treatment for patients with mutant Ras multiple myeloma, a challenging form of cancer. The approach utilizes a unique drug conjugate that targets cancer cells displaying high levels of macropinocytosis, allowing for effective delivery of a cytotoxic agent directly to the tumor. The research includes preclinical studies to assess the drug's effectiveness and safety before advancing to clinical trials. Patients with this specific mutation may benefit from a targeted therapy that addresses their cancer's resistance to current treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with mutant Ras multiple myeloma who have experienced treatment resistance.
Not a fit: Patients without the mutant Ras mutation or those with other types of multiple myeloma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients with mutant Ras multiple myeloma, potentially improving survival rates.
How similar studies have performed: Other research has shown promise in targeting macropinocytosis in cancer treatment, indicating potential for success with this novel approach.
Where this research is happening
NEW HAVEN, UNITED STATES
- TEZCAT LABORATORIES LLC — NEW HAVEN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: RAMIREZ, CRAIG PATRICK — TEZCAT LABORATORIES LLC
- Study coordinator: RAMIREZ, CRAIG PATRICK
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.